Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127245181 | 12724518 | 1 | I | 20160811 | 0 | 20160908 | 20160908 | DIR | US-FDA-349857 | FDA-CTU | 43.00 | YR | M | N | 96.75000 | KG | 20160906 | N | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127245181 | 12724518 | 1 | PS | NICODERM CQ | NICOTINE | 1 | Transdermal | Y | D | 1511476 | 20170801 | 0 | 21 | MG/KG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127245181 | 12724518 | 1 | Smoking cessation therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127245181 | 12724518 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127245181 | 12724518 | Application site erythema | |
| 127245181 | 12724518 | Application site irritation | |
| 127245181 | 12724518 | Application site vesicles | |
| 127245181 | 12724518 | Necrosis | |
| 127245181 | 12724518 | Product contamination | |
| 127245181 | 12724518 | Type IV hypersensitivity reaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127245181 | 12724518 | 1 | 20160804 | 20160811 | 0 |